TABLE 2.
Author (year) | Study cohort | Geriatric assessment tool/cut‐off value (% of frail patients) | Postoperative complications | Postoperative mortality | Length of hospital stay | Patient survival |
---|---|---|---|---|---|---|
Gastric cancer | ||||||
Tanaka et al (2019) |
|
|
NS | NS | NS |
↓ OS: HR 3.4 (95%CI, 1.4‐8.2) CSS: HR 4.0 (95%CI, 1.2‐13.3) |
Colorectal cancer | ||||||
Tamura et al (2021) |
|
|
↑ (CD ≥I, 28% vs 15%, P = 0.001) |
– | – | – |
Bessems et al (2021) |
|
|
↑ (CD ≥I, 62% vs 28%, P < 0.001) |
NS |
↑ (9 days vs 8 days, P = 0.009) |
– |
Mima et al (2020) |
|
|
NS | NS | – |
↓ OS: HR 2.0 (95%CI, 1.4‐3.0) RFS: HR 1.7 (95%CI, 1.3‐2.3) |
Okabe et al (2019) |
|
|
↑ (CD III/IV, 23% vs 8%, P = 0.001) |
NS |
↑ (13 days vs 10 days, P < 0.001) |
– |
Fagard et al (2017) |
|
|
↑ (CD ≥II, 48% vs 31%, P = 0.020) |
– | – | – |
Reisinger et al (2015) |
|
|
↑ (Sepsis, 15% vs 4.4%, P = 0.03) |
NS | – | – |
Ommundsen et al (2014) |
|
|
– | – | – |
↓ OS: HR 3.6 (95%CI, 2.3‐5.5) |
Tan et al (2012) |
|
|
↑ (CD ≥II, 48% vs 18%, P = 0.006) |
– | – | – |
Kristjansson et al (2010) |
|
|
↑ (CD ≥II, 62% vs 33%, P = 0.002) |
– | – | – |
Note: ↑, higher incidence of postoperative complications or mortality, and longer length of hospital stay in frail patients; ↓, shorter overall, cancer‐specific, or recurrence‐free survival in frail patients; −, not examined.
Abbreviations: CD, Clavien‐Dindo grade; CI, confidence interval; CSS, cancer‐specific survival; HR, hazard ratio; NS, not significant (P > 0.05); OS, overall survival; RFS, recurrence‐free survival.